secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001193125-25-058979
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics appoints Erick Lucera as CFO; outgoing CFO Richard Scalzo to consult
--------------------------------------------------------------------------------

- Erick Lucera named CFO and Treasurer, effective March 31, 2025; previously CFO of Editas Medicine and AVEO Pharmaceuticals.
- Lucera receives base salary $520k, bonus up to 40%, and inducement equity: 214,500 stock options + 66,100 RSUs.
- Richard Scalzo steps down as SVP Finance & Treasurer same date; will provide consulting services for up to 6 months.
- Scalzo's unvested equity to continue vesting during consultancy; stock option exercise period extended to 6 months post-consulting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525058979/0001193125-25-058979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525058979/d788212d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-058979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer